Management of acute, severe ulcerative colitis

Area of Science:

• Gastroenterology
• Colorectal Surgery

Background:

• Acute, severe ulcerative colitis hospitalization necessitates a critical decision: immediate surgery or medical management.
• Failure to respond to initial medical therapy (IV steroids, antibiotics, supportive care) within 3-5 days occurs in 15-50% of patients, requiring re-evaluation.

Purpose of the Study:

• To outline the decision-making process for managing acute, severe ulcerative colitis, focusing on the choice between colectomy and medical salvage therapy.
• To highlight the critical timing and considerations for selecting non-operative salvage strategies.

Main Methods:

• Review of indications for immediate colectomy (hemorrhage, perforation, cancer).
• Discussion of medical salvage therapy options, including cyclosporine and infliximab.
• Consideration of factors influencing the choice between surgery and salvage therapy, such as time, post-hospital remission strategy, and colon viability.

Main Results:

• Absolute indications for colectomy are exsanguinating hemorrhage, perforation, and cancer.
• Medical salvage therapy is considered when initial treatment fails, with cyclosporine and infliximab as primary options.
• Ongoing trials (GETAID, CONSTRUCT) are expected to provide further evidence supporting treatment modalities.

Conclusions:

• The decision between colectomy and medical salvage therapy for severe ulcerative colitis must be prompt.
• Salvage therapy requires careful consideration of time, long-term remission strategies, and the potential for colon preservation.
• The ultimate priority in managing severe ulcerative colitis is patient survival over organ preservation.